Ownership Summary
The institutional landscape for China Pharma Holdings, Inc. (NYSE:CPHI) includes 5 filers as of the latest reporting cycle ending September 2025.
- Institutional ownership in China Pharma Holdings edged down to 1.6% in September 2025, compared to 3.8% in June 2025.
- The company experienced a -15.38% quarterly change in institutional shares held, alongside no change in total owners annually.
- During the quarter, 3 institutions bought more China Pharma Holdings shares, 1 sold shares, and 1 of the 5 total investors held their position steady.
- This class of investors decreased its holdings in China Pharma Holdings to 60.28K shares for the 13F-cycle ending September 2025, down by 10.96K shares quarter on quarter, and up 19.61K shares year over year.
- With 30.43K shares, CITADEL ADVISORS LLC commands the largest institutional position in China Pharma Holdings as of September 30, 2025, equating to 0.79% of the company.
- Among the most significant buyers of China Pharma Holdings during September 2025 were CITADEL ADVISORS LLC (30.43K), RENAISSANCE TECHNOLOGIES LLC (10.62K), JPMORGAN CHASE & CO (40).
- Leading sellers of China Pharma Holdings stock in September 2025 included UBS Group AG (52.04K).
- The top 5 institutional holders of China Pharma Holdings for the quarter ending September 2025 included CITADEL ADVISORS LLC (30.43K), UBS Group AG (19.19K), RENAISSANCE TECHNOLOGIES LLC (10.62K), JPMORGAN CHASE & CO (40), DANSKE BANK A/S (1).